The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 2754692 |
20 |
Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted benzolactams. |
Merck Sharp & Dohme Research Laboratories |
| 2477546 |
16 |
Synthesis and biological activity of some partially modified retro-inverso analogues of cholecystokinin. |
Centre De Pharmacologie-Endocrinologie (Montpellier, France) |
| 3336026 |
18 |
Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted 1,4-benzodiazepin-2-amines. |
Merck Sharp & Dohme Research Laboratories |
| 2441054 |
18 |
Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds. |
TBA |
| 3761313 |
22 |
Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility. |
TBA |
| 26654202 |
99 |
Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex. |
Mayo Clinic |
| 21689940 |
35 |
Synthesis and structure-activity relationship of new 1,5-dialkyl-1,5-benzodiazepines as cholecystokinin-2 receptor antagonists. |
Glaxosmithkline |
| 7932591 |
69 |
Three-dimensional molecular shape analysis-quantitative structure-activity relationship of a series of cholecystokinin-A receptor antagonists. |
University of Illinois At Chicago |
| 22424974 |
35 |
Discovery of new piperidine amide triazolobenzodiazepinones as intestinal-selective CCK1 receptor agonists. |
Pfizer |
| 15456276 |
45 |
5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors. |
Instituto De Qu£Mica M£Dica (Csic) |
| 12477342 |
27 |
2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery. |
Merck Research Laboratories |
| 11708921 |
28 |
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structure-activity relationship studies on the central 1,3-dioxoperhydropyrido[1,2-c]pyrimidine scaffold. |
Instituto De Qu£Mica M£Dica (Csic) |
| 11405658 |
12 |
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1)receptor antagonists: structure-activity relationship studies on the substituent at N2-position. |
Instituto De Qu£Mica M£Dica (Csic) |
| 11020292 |
34 |
beta-Turned dipeptoids as potent and selective CCK(1) receptor antagonists. |
Instituto De Qu£Mica M£Dica (Csic) |
| 11000005 |
16 |
Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists. |
James Black Foundation |
| 10882360 |
17 |
CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists. |
Astrazeneca R&D Boston |
| 10579828 |
28 |
5-(Tryptophyl)amino-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based potent and selective CCK(1) receptor antagonists: structural modifications at the tryptophan domain. |
Insituto De Qu�Mica M�Dica (Csic) |
| 9438020 |
67 |
Second generation"peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. |
Warner-Lambert |
| 9435899 |
18 |
Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents. |
Rochester |
| 8568800 |
155 |
Structure-antigastrin activity relationships of new spiroglumide amido acid derivatives. |
Rotta Research Laboratorium |
| 8145219 |
20 |
High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing group. |
Merck Sharp and Dohme Research Laboratories |
| 7684452 |
66 |
Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and"mixed" CCK-A/CCK-B antagonists. |
Parke-Davis Neuroscience Research Centre |
| 8277510 |
233 |
Development of 1,4-benzodiazepine cholecystokinin type B antagonists. |
Merck Research Laboratories |
| 1573640 |
54 |
Amide bond replacements incorporated into CCK-B selective"dipeptoids". |
Parke-Davis Neuroscience Research Center |
| 1635058 |
50 |
Rationally designed"dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988. |
Parke-Davis Neuroscience Research Centre |
| 1732532 |
139 |
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives. |
Rotta Research Laboratorium |
| 1671419 |
48 |
Rationally designed"dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. |
Parke-Davis Research Unit |
| 2299627 |
54 |
Novel glutamic acid derived cholecystokinin receptor ligands. |
Merck Sharp & Dohme Research Laboratories |
| 2909725 |
42 |
Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. |
Merck Sharp & Dohme Research Laboratories |
| 2848124 |
401 |
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. |
Merck Sharp & Dohme Research Laboratories |
| 2885419 |
179 |
Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists. |
TBA |
| 10866391 |
10 |
The design and synthesis of the high efficacy, non-peptide CCK1 receptor agonist PD170292. |
Ccipe-Faculte De Pharmacie |
| 9873689 |
12 |
Structurally similar small molecule photoaffinity CCK-A agonists and antagonists as novel tools for directly probing 7TM receptors-ligand interactions. |
Neurogen |
| | 32 |
Pseudopeptide CCK-4 analogues incorporating the [CH(CN)NH] peptide bond surrogate |
TBA |
| | 66 |
Design and synthesis of a targeted set of aromatic amino acid derivatives for identification of new lead compounds |
TBA |
| | 31 |
Identification and biological activity of novel peptidomimetic gastrin/CCK-B receptor agonists |
TBA |
| | 10 |
Synthesis of novel iodinated radioligands with high affinity and selectivity for CCK-B/gastrin receptors |
TBA |
| | 27 |
The rational design and synthesis of non-peptide rhegnylogues of CCK-26-33 - a novel series of CCK-A selective ligands |
TBA |
| | 7 |
Synthesis of a potent and selective non-peptide CCK-B/gastrin receptor antagonist tritiated ligand. |
TBA |
| | 27 |
Biological properties of (R)-4-benzamido-5-oxopentanoic basic derivatives as CCK-antagonists |
TBA |
| 21728335 |
20 |
New anthranilic acid based antagonists with high affinity and selectivity for the human cholecystokinin receptor 1 (hCCK1-R). |
University of Trieste |
| 20851601 |
28 |
Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity. |
Pfizer |
| 19523833 |
33 |
2D-QSAR and 3D-QSAR/CoMFA analyses of the N-terminal substituted anthranilic acid based CCK(1) receptor antagonists: 'Hic Rhodus, hic saltus'. |
Aristotelian University of Thessaloniki |
| | 22 |
Design and synthesis of novel nonpeptide CCK-B receptor antagonists |
TBA |
| | 28 |
Dual CCK-A and -B receptor antagonists (I) C9-methyl-1,4-benzodiazepines |
TBA |
| | 38 |
SAR study of the indole moiety of CI-988, a potent and selective CCK-B antagonist |
TBA |
| | 30 |
CCK-4 restricted analogues containing a 3-oxoindolizidine skeleton |
TBA |
| | 29 |
Synthesis and biological activity of 5-heteroaryl benzodiazepines: analogues of YM022 |
TBA |
| | 25 |
Synthesis and biological activity of 1-alkylcarbonylmethyl analogues of YM022 |
TBA |
| | 27 |
C5-piperazinyl-1,4-benzodiazepines, water-soluble, orally bioa vailable CCKB/gastrin receptor antagonists |
TBA |
| | 6 |
CCKB selective receptor ligands: novel 1,3,5-trisubstituted benzazepin-2-ones |
TBA |
| | 13 |
Alternative strategies towards the identification of chemical lead compounds by rational design |
TBA |
| | 23 |
Methionine replacements in biologically active peptides |
TBA |
| | 12 |
α-β-didehydrotryptophan as a surrogate for α-methyltryptophan in CCK ‘peptoids’ related to CI-988. |
TBA |
| | 24 |
Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class |
TBA |
| | 24 |
Diphenylpyrazolidinone and benzodiazepine cholecystokinin antagonists: A case of convergent evolution in medicinal chemistry |
TBA |
| | 55 |
Benzolactams as non-peptide cholecystokinin receptor ligands |
TBA |
| | 54 |
Multipurpose receptor ligands: β-carboline cholecystokinin antagonists |
TBA |
| | 11 |
Diastereoselective synthesis of cyclopropyl phenylalanines and their incorporation into dipeptides |
TBA |
| | 34 |
Synthesis and sar study of novel CCK-B antagonists |
TBA |
| | 10 |
L-708,474: The C5-cyclohexyl analogue of L-365,260, a selective high affinity ligand for the CCKB/gastrin receptor |
TBA |
| | 8 |
The use of a proline ring as a conformational restraint in CCK-B receptor “dipeptoids”. |
TBA |
| | 17 |
1,3,4-trisubstituted pyrrolidinones as scaffolds for construction of peptidomimetic cholecystokinin antagonists |
TBA |
| | 14 |
The synthesis and CCK receptor affinities of selected carboyxlic acid mimics of CI-988 - a potent and selective CCK-B antagonist |
TBA |
| 19261479 |
21 |
Anthranilic acid based CCK1 receptor antagonists: blocking the receptor with the same 'words' of the endogenous ligand. |
University of Trieste |
| 17368898 |
6 |
Synthesis and evaluation of novel benzimidazole derivative [Bz-Im] and its radio/biological studies. |
Lucknow University |
| 16451051 |
5 |
Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor. |
Mayo Clinic |
| 16302807 |
34 |
Conformationally constrained CCK4 analogues incorporating IBTM and BTD beta-turn mimetics. |
Instituto De QuíMica MéDica (Csic) |
| 16033264 |
48 |
Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor. |
Instituto De QuíMica MéDica (Csic) |
| 11755332 |
10 |
Effects of the incorporation of IBTM beta-turn mimetics into the dipeptoid CCK(1) receptor agonist PD 170292. |
Instituto De QuíMica MéDica (Csic) |
| 9990454 |
26 |
Highly constrained dipeptoid analogues containing a type II' beta-turn mimic as novel and selective CCK-A receptor ligands. |
Instituto De QuíMica MéDica (Csic) |
| 9873368 |
8 |
Relationship between dihedral angles of N1 and C9 substituents in 1,4-benzodiazepines and dual cholecystokinin-A and -B antagonistic activities. |
Fujisawa Pharmaceutical |
| 9544204 |
100 |
Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists. |
Parke-Davis Pharmaceutical Research |
| 9341915 |
24 |
Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists. |
Instituto De QuíMica MéDica (Csic) |
| 9258356 |
34 |
5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor. |
Merck Sharp & Dohme Research Laboratories |
| 9022799 |
38 |
(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. |
Ferring Research Institute |
| 8632410 |
33 |
Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors. |
Universitá |
| 8632408 |
24 |
Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas. |
Neuroscience Research Centre |
| 8411002 |
67 |
Cholecystokinin peptidomimetics as selective CCK-B antagonists: design, synthesis, and in vitro and in vivo biochemical properties. |
University of Paris |
| 8246239 |
84 |
Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives. |
Solvay Duphar |
| 8145220 |
16 |
Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. |
Merck Research Laboratories |
| 7837225 |
40 |
Ac-[3- and 4-alkylthioproline31]-CCK4 analogs: synthesis and implications for the CCK-B receptor-bound conformation. |
Washington University |
| 6094810 |
6 |
Synthesis and biological activity of new peptide segments of gastrin exhibiting gastrin antagonist property. |
TBA |
| 3336017 |
28 |
Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines. |
Merck Sharp & Dohme Research Laboratories |
| 2438407 |
14 |
Investigation of peripheral cholecystokinin receptor heterogeneity by cyclic and related linear analogues of CCK26-33: synthesis and biological properties. |
TBA |
| 2153212 |
87 |
Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom. |
Merck Sharp & Dohme Research Laboratories |
| 2002454 |
32 |
Carboxylic acids and tetrazoles as isosteric replacements for sulfate in cholecystokinin analogues. |
Roche Research Center |
| 1552499 |
23 |
Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718. |
Center For Bio-Pharmaceutical Sciences |
| 1433225 |
18 |
Analogs of CCK incorporating conformationally constrained replacements for Asp32. |
Roche Research Center |
| 1433191 |
25 |
Analogs of Ac-CCK-7 incorporating dipeptide mimics in place of Met28-Gly29. |
Roche Research Center |
Search and Browse
